Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
CapEx to Revenue
5.14%
Quarterly · Period ending:
LCTX CapEx to Revenue
Latest reported5.14%period ending
Latest reported5.14%period ending
LCTX Quarterly CapEx/Revenue (0.00% → 5.14%)
Latest values, visible window
High-resolution chart · PNG
LCTX capex to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | CapEx to Revenue |
|---|---|
| 5.145% | |
| 3.1884% | |
| 1.6798% | |
| 0.326% | |
| 0.5063% | |
| 6.4581% | |
| 12.7266% | |
| 2.9637% | |
| 3.5511% | |
| 2.6316% | |
| 4.3582% | |
| 11.1557% | |
| 7.938% | |
| 7.8793% | |
| 0.8355% | |
| 9.5397% | |
| 2.1305% | |
| 0.8784% | |
| 15.2083% | |
| 3.0881% | |
| 26.0771% | |
| 3.7543% | |
| 14.4578% | |
| 7.0175% | |
| 6.0606% | |
| 6.0241% | |
| 0.8413% | |
| 31.7972% | |
| 78% | |
| 94.4134% | |
| 594.152% | |
| 467.4242% | |
| 6.4356% | |
| 266.1333% | |
| 69.5958% | |
| 98.4881% | |
| 70.6037% | |
| 54.0897% | |
| 51.1873% | |
| 122.0513% | |
| 160.4743% | |
| 145.0512% | |
| 178.3784% | |
| 181.0714% | |
| 428.2537% | |
| 66.0147% | |
| 3.1567% | |
| 17.0131% | |
| 37.0132% | |
| 47.2367% | |
| 23.8916% | |
| 224.1417% | |
| 45.7107% | |
| 94.6544% | |
| 37.7631% | |
| 5.1462% | |
| 3.5686% | |
| 18.4514% | |
| 11.0204% | |
| 21.2208% | |
| 32.0525% | |
| 36.0508% | |
| 18.9808% | |
| 2.6576% | |
| 16.174% | |
| 32.5568% | |
| 3.5505% | |
| 5.7343% | |
| 1.3365% | |
| 1.0999% | |
| 300.9261% | |
| 58.5575% | |
| 60.892% | |
| 0.3645% | |
| 1.3093% | |
| 0% | |
| 0% | |
| 0.7241% | |
| 0.9834% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |